Most amyloid-related imaging abnormalities (ARIA) occurring in Alzheimer’s patients receiving Aduhelm (aducanumab) are temporary, moderate in severity, and asymptomatic (without symptoms), according to an analysis of data from the Phase 3 ENGAGE and EMERGE trials. Most ARIA-edema (ARIA-E), or fluid accumulation in the brain, occurred within the first eight doses (six months) of Aduhelm treatment, supporting current recommendations of MRI scans before dose seven and dose 12. These findings, along with additional efficacy and biomarker…
You must be logged in to read/download the full post.
The post #AAIC21 – Most Aduhelm-linked Imaging Abnormalities Seen as Asymptomatic appeared first on BioNewsFeeds.